Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenome 2.0 Offers Better Bioinformatics Platform, More Data

Premium

WALTHAM, Mass.--Genome Therapeutics here has released version 2.0 of PathoGenome, the company's proprietary microbial sequence database. The new version uses a more powerful and efficient bioinformatics platform and features highly finished genomic sequence information for more than a dozen pathogens, according to the company.

The upgraded PathoGenome is currently being installed at the research facilities of the database's subscribers, who include Bayer, Bristol-Myers Squibb, and Schering-Plough. The original version was introduced in May. "The feedback we've received from our customers has been excellent, with reports of new potential antiinfective targets already identified. This rapid success underscores the power of comparative genomics to define targets that are common to multiple organisms," commented Robert Hennessey, Genome Therapeutics' chairman, president, and CEO.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.